MONTREAL, QUEBEC--(MARKET WIRE)--Jun 4, 2007 -- Theratechnologies (Toronto:TH.TO - News) reported today that 26-week data from its first Phase 3 study testing TH9507 in HIV-associated lipodystrophy were presented today in Toronto at ENDO, the 89th annual meeting of the Endocrine Society. The presentation was made by Dr. Steve Grinspoon, Associate Professor of Medicine, Harvard Medical School and lead investigator for the TH9507 trial in the United States.
